HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2,3-dinor-thromboxane B2

Also Known As:

2,3-dinor TxB2; 3-Pentenoic acid, 5-(tetrahydro-4,6-dihydroxy-2-(3-hydroxy-1-octenyl)-2H-pyran-3-yl)-, (2R-(2alpha(1E,3S*),3beta(Z),4beta,6alpha))-

Networked: 9 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - Unsaturated Fatty Acids: 8236
    - Eicosanoids: 3262
      - Arachidonic Acids: 122
        Thromboxanes: 2439
        Thromboxane B2: 964
        2,3-dinor-thromboxane B2: 9
    - Essential Fatty Acids: 734
      - Arachidonic Acids: 122
        Thromboxanes: 2439
        Thromboxane B2: 964
        2,3-dinor-thromboxane B2: 9

Related Diseases

1.	Myocardial Infarction 06/01/1986 - "During acute myocardial infarction excretion of 2,3-dinor-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha, measured by a gas chromatography-mass spectrometry method with deuterated internal standards, was significantly increased. " 10/15/1993 - "Excretion of 2,3-dinor-thromboxane B2 released from activated platelets has been found elevated in patients with acute myocardial infarction and unstable angina. " 06/01/1986 - "The in vivo production of prostacyclin and thromboxane was monitored by measuring their major urinary metabolites 2,3-dinor-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in ten patients with acute myocardial infarction, five on standard treatment and five receiving prostacyclin infusion. "
2.	Unstable Angina 11/01/1987 - "Therefore, urinary excretion of their major metabolites, 2,3-dinor-thromboxane B2 and 2,3-dinor-6-ketoprostaglandin F1 alpha, was studied in 16 patients presenting with prolonged angina at rest. " 10/15/1993 - "Excretion of 2,3-dinor-thromboxane B2 released from activated platelets has been found elevated in patients with acute myocardial infarction and unstable angina. "
3.	Thrombocytopenia (Thrombopenia) 09/01/1981 - "Despite marked thrombocytopenia and continued treatment with aspirin, sulfinpyrazone, and dipyridamole, the urinary excretion of 2,3-dinor-thromboxane B2, a major thromboxane urinary metabolite, was within the normal range (90.3 to 368 pg/mg creatinine) at 96 pg/mg creatinine. "
4.	Systemic Scleroderma (Systemic Sclerosis) 04/19/1986 - "Excretion of the major urinary thromboxane metabolite, 2,3-dinor-thromboxane B2, was significantly increased (p less than 0.001) in 10 patients (nine women) with systemic sclerosis complicated by Raynaud's phenomenon compared with healthy controls (486 (SD 88) v 162 (38) ng/g creatinine) and increased further in the patients (to 1007 (212) ng/g creatinine) during application of a cold stimulus sufficient to induce digital vasoconstriction. "
5.	Pulmonary Hypertension 01/01/1990 - "The excretion rates of this compound as well as of 2,3-dinor-thromboxane B2, a major metabolite of thromboxane A2, in two newborns with septic persistent pulmonary hypertension were about 30- to 50-fold higher than the normal range (2,3-dinor-6-oxo-prostaglandin F1 alpha: 3-15 ng/h/1.73 m2; 2,3-dinor-thromboxane B2: 8-25 ng/h/1.73 m2). "

Related Drugs and Biologics

1.	Creatinine
2.	Thromboxanes
3.	Thromboxane B2
4.	Thromboxane A2 (A2, Thromboxane)
5.	Sulfinpyrazone (Anturane)
6.	Epoprostenol (Prostacyclin)
7.	Insulin (Novolin)
8.	Dipyridamole (Persantine)
9.	Aspirin (Acetylsalicylic Acid)
10.	prostaglandin F1

Related Therapies and Procedures

1.	Artificial Pancreas